Compliance with hepatocellular carcinoma screening and the effectiveness of screening in cirrhotic patients

Ümit Yavuz Keleş; Sami Fidan; Seher Nazlı Kazaz; Murat Erkut; Arif Mansur Coşar

Makale detayları

Compliance with hepatocellular carcinoma screening and the effectiveness of screening in cirrhotic patients

Yazarlar:

Ümit Yavuz Keleş | Sami Fidan | Seher Nazlı Kazaz | Murat Erkut | Arif Mansur Coşar

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Gastroenterology and Hepatology | Clinical Oncology

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 2, pp.152-158

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001353129

pISSN:

1309-4483

Anahtar kelimeler:

Özet:

 Current guidelines recommend that patients with cirrhosis be screened for the development of HCC every 6 months. The aim of our study was to determine whether HCC screening is performed with appropriate methods and at appropriate intervals in cirrhotic patients, and to evaluate the outcomes of the screening. This research is a retrospective cohort study. The study included patients aged 18 and over, diagnosed with Child-Pugh class A or B cirrhosis, who applied to our clinic between 2010 and 2020. Patients were divided into two groups: those who underwent guideline-recommended surveillance imaging with ultrasound, CT, or MRI andor measurement of AFP every 4-8 months and those who did not undergo recommended surveillance insufficient screening or no screening. These groups were compared in terms of HCC development, curative treatment, and survival. A total of 641 cirrhotic patients were included in the study. Only 146 22.7 patients underwent guideline-recommended HCC screening. During the follow-up period, a total of 89 patients were diagnosed with HCC 42 patients 28.8 in the surveillance group and 47 patients 9.5 in the nonsurveillance group, p0.001. In the surveillance group, the rate of early-stage HCC detection 83.3 vs. 40.4, curative treatment rate 78.4 vs. 33.3, and median survival time 74 vs. 21.7 months were higher compared to the nonsurveillance group p0.001. HCC screening rates in cirrhotic patients are quite low. Guideline-recommended HCC screening in these patients results in earlier diagnosis and increases both the likelihood of receiving curative treatment and overall survival.

 Current guidelines recommend that patients with cirrhosis be screened for the development of HCC every 6 months. The aim of our study was to determine whether HCC screening is performed with appropriate methods and at appropriate intervals in cirrhotic patients, and to evaluate the outcomes of the screening. This research is a retrospective cohort study. The study included patients aged 18 and over, diagnosed with Child-Pugh class A or B cirrhosis, who applied to our clinic between 2010 and 2020. Patients were divided into two groups: those who underwent guideline-recommended surveillance imaging with ultrasound, CT, or MRI andor measurement of AFP every 4-8 months and those who did not undergo recommended surveillance insufficient screening or no screening. These groups were compared in terms of HCC development, curative treatment, and survival. A total of 641 cirrhotic patients were included in the study. Only 146 22.7 patients underwent guideline-recommended HCC screening. During the follow-up period, a total of 89 patients were diagnosed with HCC 42 patients 28.8 in the surveillance group and 47 patients 9.5 in the nonsurveillance group, p0.001. In the surveillance group, the rate of early-stage HCC detection 83.3 vs. 40.4, curative treatment rate 78.4 vs. 33.3, and median survival time 74 vs. 21.7 months were higher compared to the nonsurveillance group p0.001. HCC screening rates in cirrhotic patients are quite low. Guideline-recommended HCC screening in these patients results in earlier diagnosis and increases both the likelihood of receiving curative treatment and overall survival.

 Current guidelines recommend that patients with cirrhosis be screened for the development of HCC every 6 months. The aim of our study was to determine whether HCC screening is performed with appropriate methods and at appropriate intervals in cirrhotic patients, and to evaluate the outcomes of the screening. This research is a retrospective cohort study. The study included patients aged 18 and over, diagnosed with Child-Pugh class A or B cirrhosis, who applied to our clinic between 2010 and 2020. Patients were divided into two groups: those who underwent guideline-recommended surveillance imaging with ultrasound, CT, or MRI andor measurement of AFP every 4-8 months and those who did not undergo recommended surveillance insufficient screening or no screening. These groups were compared in terms of HCC development, curative treatment, and survival. A total of 641 cirrhotic patients were included in the study. Only 146 22.7 patients underwent guideline-recommended HCC screening. During the follow-up period, a total of 89 patients were diagnosed with HCC 42 patients 28.8 in the surveillance group and 47 patients 9.5 in the nonsurveillance group, p0.001. In the surveillance group, the rate of early-stage HCC detection 83.3 vs. 40.4, curative treatment rate 78.4 vs. 33.3, and median survival time 74 vs. 21.7 months were higher compared to the nonsurveillance group p0.001. HCC screening rates in cirrhotic patients are quite low. Guideline-recommended HCC screening in these patients results in earlier diagnosis and increases both the likelihood of receiving curative treatment and overall survival.

 Current guidelines recommend that patients with cirrhosis be screened for the development of HCC every 6 months. The aim of our study was to determine whether HCC screening is performed with appropriate methods and at appropriate intervals in cirrhotic patients, and to evaluate the outcomes of the screening. This research is a retrospective cohort study. The study included patients aged 18 and over, diagnosed with Child-Pugh class A or B cirrhosis, who applied to our clinic between 2010 and 2020. Patients were divided into two groups: those who underwent guideline-recommended surveillance imaging with ultrasound, CT, or MRI andor measurement of AFP every 4-8 months and those who did not undergo recommended surveillance insufficient screening or no screening. These groups were compared in terms of HCC development, curative treatment, and survival. A total of 641 cirrhotic patients were included in the study. Only 146 22.7 patients underwent guideline-recommended HCC screening. During the follow-up period, a total of 89 patients were diagnosed with HCC 42 patients 28.8 in the surveillance group and 47 patients 9.5 in the nonsurveillance group, p0.001. In the surveillance group, the rate of early-stage HCC detection 83.3 vs. 40.4, curative treatment rate 78.4 vs. 33.3, and median survival time 74 vs. 21.7 months were higher compared to the nonsurveillance group p0.001. HCC screening rates in cirrhotic patients are quite low. Guideline-recommended HCC screening in these patients results in earlier diagnosis and increases both the likelihood of receiving curative treatment and overall survival.

Makale detayları

Compliance with hepatocellular carcinoma screening and the effectiveness of screening in cirrhotic patients

Yazarlar:

Ümit Yavuz Keleş | Sami Fidan | Seher Nazlı Kazaz | Murat Erkut | Arif Mansur Coşar

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Gastroenterology and Hepatology | Clinical Oncology

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 2, pp.152-158

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001353129

pISSN:

1309-4483

Surveillance

Screening

Hepatocellular carcinoma

Cirrhosis

Sayı

Makale detayları

Compliance with hepatocellular carcinoma screening and the effectiveness of screening in cirrhotic patients

Yazarlar: Ümit Yavuz Keleş | Sami Fidan | Seher Nazlı Kazaz | Murat Erkut | Arif Mansur Coşar

Yayıncı: Ondokuz Mayıs University

Ana Başlıklar: Gastroenterology and Hepatology | Clinical Oncology

Dergi: Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 2, pp.152-158

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001353129

pISSN: 1309-4483

Surveillance

Screening

Hepatocellular carcinoma

Cirrhosis

Sayı

Yazarlar:

Ümit Yavuz Keleş | Sami Fidan | Seher Nazlı Kazaz | Murat Erkut | Arif Mansur Coşar

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Gastroenterology and Hepatology | Clinical Oncology

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 2, pp.152-158

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001353129

pISSN:

1309-4483